SCHEMBL179940

SCHEMBL179940

COCCCCCCCCCCC[C]=O

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7340991 1.00 ALDH1A1 (0.44) ALDH1A1TSHR
SCHEMBL2094911 1.00
SCHEMBL9479478 1.00 ALDH1A1 (0.44) ALDH1A1TSHR
SCHEMBL2091621 0.97
SCHEMBL1446393 0.89
SCHEMBL1714641 0.83 ALDH1A1 (0.50) ALDH1A1TSHR
SCHEMBL8812303 0.83 ALDH1A1 (0.32) ALDH1A1
SCHEMBL8810614 0.83 ALDH1A1 (0.32) ALDH1A1
SCHEMBL8810576 0.83 ALDH1A1 (0.32) ALDH1A1
SCHEMBL1714843 0.83 ALDH1A1 (0.50) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402358-A2 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs Instytut Biochemii I Biofizyki Pan (PL) 2012-01-04 EP claimed
US-6602861-B1 Acylated phospholipid drugs RESEARCH CORPORATION TECHNOLOGIES, INC. 2003-08-05 US claimed
EP-0636134-B1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RES CORP TECHNOLOGIES INC (US) 1997-12-17 EP claimed
EP-0636134-A1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-02-01 EP claimed
WO-1993021191-A1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-10-28 WO claimed
EP-2402358-A3 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs Instytut Biochemii I Biofizyki Pan (PL) 2012-07-18 EP disclosed
EP-2402358-A2 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs Instytut Biochemii I Biofizyki Pan (PL) 2012-01-04 EP disclosed
EP-2402358-A2 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs Instytut Biochemii I Biofizyki Pan (PL) 2012-01-04 EP disclosed
EP-2402356-A2 Modified 2',3'-dideoxynucleosides for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and the pharmaceutical agent containing these nucleosides Instytut Biochemii I Biofizyki Pan (PL) 2012-01-04 EP disclosed
US-20110027911-A1 SOLUBILIZATION AND STUDY OF MEMBRANE PROTEINS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2011-02-03 US disclosed
WO-2009089430-A1 SOLUBILIZATION AND STUDY OF MEMBRANE PROTEINS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-07-16 WO disclosed
US-6602861-B1 Acylated phospholipid drugs RESEARCH CORPORATION TECHNOLOGIES, INC. 2003-08-05 US disclosed
US-5846955-A Acylated phospholipid drugs RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-12-08 US disclosed
EP-0636134-B1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RES CORP TECHNOLOGIES INC (US) 1997-12-17 EP disclosed
EP-0636134-A1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-02-01 EP disclosed
WO-1993021191-A1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-10-28 WO disclosed